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 BNCT is an alternative therapy for treating cancer. The principle of 
BNCT involves a neutron boron capture and a nuclear reaction that 
produce alpha particle and Li ion with a high level of linear energy 
transfer in the tissue. It is effective in killing tumor cells. To administer 
boron in the tumor cells, a boron delivery agent is needed. Thus far, there 
are a variety of boron delivery agents that have been developed. To date, 
just two main boron-based drugs, BPA and BSH, have been used for 
clinical studies. Many other boron delivery agents have been evaluated in 
vivo and in vitro but have not been evaluated clinically. Therefore, the 
other boron delivery agents have not been used in BNCT clinical studies. 
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1. INTRODUCTION 
Cancer is a disease which abnormal cells 
grow out of control and affect different organs. 
Cancer can spread to any organs. In 2018, there 
were 9.6 million deaths in the world caused by 
cancer. The most common organs that are 
infected by cancer are the lungs, breasts, colon, 
prostate, skin, and stomach. The types of cancer 
treatments that exist are surgery, chemotherapy, 
radiotherapy, hormone therapy, targeted 
therapy, and immunotherapy. For some people, 
there are many side effects after receiving a 
treatment for cancer including nausea and 
fatigue [1.2]. To minimize side effects from the 
treatment of cancer, researchers have been 
considering called an alternative of therapy 
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cancer that can selectively destroy cancer cells 
and spare normal cells [3]. 
Boron neutron capture therapy (BNCT) is a 
binary therapy for healing cancer [4]. The 
principle mechanisms of BNCT are nuclear 
uptake and fission reaction. In BNCT, boron 
( B5
10 ) that accumulated in a tumor cell by 
applying a specific carrier is irradiated by low 
thermal energy-neutrons. The captured neutron 
in boron produces alpha particle and 𝐿𝑖3
7  
ions( B5
10  (n,α) Li3
7 ) (Fig.1) with a high level of 
linear energy transfer at tissue. So, it could be 
effective in killing tumor cells (Fig.2) [5]. 
Component BNCT that delivers boron 
selectively to the tumor cells is boron delivery 
agent. This agent must deliv\er enough of B 5
10  to 
the tumor cell to sustain ( B 5
10  (n,α) 𝐿𝑖3
7  ) capture 
reaction in order to damage tumor cell 
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efficiently. Moreover, boron must stay in tumor 
cells for a length of time and stay clear from the 
surrounding normal cells. Ideally, the tumor to 
normal cell ratio is greater than 3-4:1 [6]. In 
clinical studies of BNCT, the two main borons-
based drugs are sodium 
mercaptoundecahyhdrododecarbonate 
(Na2
10B12H11SH; Na2
10 BSH) and L-p-
boronophenylalanine (L-10BPA) used for the 
treatment of malignant brain tumors and 
malignant melanoma [5]. BNCT has been 
focused on the treatment of malignant gliomas 
and until recently, head and neck and liver 
cancers. [13].  
 
𝐻𝑒4 + 𝐿𝑖7 + 2.79 𝑀𝑒𝑉 (6%) 
                 ↑ 
𝐵10 +  𝑛𝑡ℎ (0.025 𝑒𝑉) → [ 𝐵
11 ]           (1) 
                  ↓ 
𝐻𝑒4 + 𝐿𝑖7 + 2.31 𝑀𝑒𝑉 (94%) 
↓ 
𝐿𝑖7 + 𝛾 + 0.48 𝑀𝑒𝑉 
Fig 1. Nuclear reaction occurs in boron of BNCT [9] 
 
Figure 2. Scheme application of BNCT in tumor cell 
[10] 
 
2. MATERIALS AND METHODS 
2.1 Boron Delivery Agent 
The important requirements for a boron 
delivery agent in BNCT include the following: 
1) concentration of boron in the tumor cell in the 
range of 20-35 µg per gram of the tumor cell and 
the ability to clear from the blood and normal 
cells relatively quickly, 2) low toxicity, and 3) 
selective to the tumor cell, can destroy only the 
tumor cells without affecting the healthy cells 
[7]. Based on previous study, development of a 
boron delivery agent taken three generations.  
First generation boron delivery agent 
In the 1950s and early 1960s, boric acid and 
its derivatives as delivery agents were first used 
in clinical trials. Currently, Boronophenylanine 
(BPA) and (Polyhedral mercaptoborone) BSH 
are in Phase I and Phase II clinical trials, and 
both have a long history of preclinical studies. A 
third derivative is GB-10 that is currently being 
approved by the FDA [11.5]. These first 
generation of BPA and BSH, however, were to 
be poor at tumor retention, non-selective, toxic, 
and poor at penetrating tumor.  
Second generation boron delivery agent 
In 1960’s, the second generation of boron 
delivery agents BPA and BSH entered the 
clinical trials. They had low toxicity, longer 
retention of tumor cells, and a ratio of tumor: 
normal cell greater than 1 [10]. BPA is a boron 
compound containing neutral amino acid - 
phenylalanine. BPA’s structure is analogous to 
tyrosine as a precursor for synthesizing the 
pigment melanin. It was tested as a boron 
delivery agent of BNCT for malignant 
melanoma. Based on in vitro and in vivo test, 
BPA accumulated selectively in B16 melanoma 
cells [11]. Furthermore, BPA has more 
therapeutic effect than BSH based on clinical 
trials in the US, Finland, Sweden and Japan [6]. 
BPA is utilized for experimental study on brain 
tumor therapy. According to Coderre et al.’s 
study, BPA is transported into rat gliosarcoma 
cells by a L-amino acids transporter system [2]. 
L-amino acids transporter system is highly 
expressed in brain tumor cells than in normal 
cells [14].  BPA has been mixed with fructose 
(L-BPA-F) in order to obtain high solubility in 
water and is improved with 10B [8].  
BSH molecule that localize selectively in 
brain tumors and penetrates the disrupted blood 
brain barrier by passive diffusion. BSH couldn’t 
cross the intact BBB [8]. BSH doesn’t have 
specific transporter to the tumor, but BSH per 
molecule could carry molecule 𝐵5
10  12 times 
more than BPA [14]. In vitro, BSH accumulated 
in the cytoplasm and the nucleus of cells [11].  
Otersen et al explains BSH has a negative 
charge by quaternary ammonium salts that can 
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bind to the positive charge of choline residues 
on phospholipids, which occur in membrane 
that contains phosphatidylcholine and 
spignomyeline. Choline is more highly 
expressed in tumor cells than in the white matter 
of normal cells [15].  
Third generation boron delivery agent 
A new number of boron delivery agents 
have been developed recently in order to deliver 
boron selectively to the target and to obtain a 
therapeutic concentration of boron [6]. Third 
generation boron delivery agents have better 
stability and selectivity than previous 
generations. The strategy to develop a boron 
delivery agent is incorporate it with a compound 
that has selectivity and specificity to the target 
such as peptides, proteins, antibodies, 
nucleosides, sugars, porphyrins, liposomes and 
nanoparticles [16]. 
3. RESULTS AND DISCUSSION 
These are some of boron delivery agents 
with their current status. 
 
Table 1. Summary of new boron delivery agents 
Boron 
Delivery 
Agent 
Mechanism of 
Localization 
Current 
status 
BPA Uptake by L-type 
amino acid transporters 
and cell membrane 
diffusion [20]. 
Clinical 
studies 
[17] 
BSH Accumulate in tumor 
cells by passive 
transport with the 
destruction of the blood 
brain barrier (BBB) 
[30].  
Clinical 
studies 
[17] 
Nucleoside 
and 
Carbohydrate 
Analog 
Localize in tumor cells 
by kinase mediated 
trapping [24]. 
Thymidine kinase 
(TK1) is highly 
expressed in a tumor 
cell that is actively 
proliferating [22, 23].  
Preclinical 
studies [22, 
23]  
Unnatural 
Amino Acids 
(ABCPC and 
ACBC) 
Uptake by L-type 
amino acids 
transporters like 
phenylalanine [14].  
Preclinical 
studies 
[14] 
Cationic 
Polymers 
Cationic polymer 
attracts to the anionic 
charge around the 
tumor cell that is 
Preclinical 
studies 
[27]. 
expressed in sialic acid 
[27].  
Porphyrin 
Derivatives 
Accumulates in tumor 
cells via endosomal 
distribution and leaky 
vasculature [17].  
Preclinical 
studies 
[21] 
Liposome Localizes in tumor cells 
via EPR effect [28]. 
Cationic liposomes 
attract the negative 
charge of the outer layer 
of mammalian plasma 
membranes by 
electrostatic 
interactions [29].  
Preclinical 
studies 
[28] 
Nanoparticles Accumulate in tumor 
cells by their EPR 
(Enhanced 
Permeability and 
Retention) effect [31].  
Preclinical 
studies 
[31].  
Monoclonal 
antibody 
Monoclonal antibody, 
like cetuximab, is 
attractive to and binds 
with EGF receptors or 
EGFRvIII, which are 
overexpressed in 
human glioblastomas 
[26].  
Preclinical 
studies [25, 
26] 
Cell 
Penetrating 
Peptides 
Localize in tumor cells 
via electrostatic 
interaction with plasma 
membrane and 
penetrating by 
micropinocytosis [32]. 
Preclinical 
studies 
[33].  
 
In Indonesia, the development of new boron 
delivery agents for BNCT focuses on healing 
common cancers such as ovarian, cervical, 
breast, thyroid, skin, and soft tissue cancers. 
[34]. The faculty of Pharmacy Universitas 
Gadjah Mada have been developing a new 
boron delivery agent, pentagamaboronon-0 
(PGB-0) which is curcumin analogous to that 
used for the treatment of breast cancer with 
positive HER2 [35]. The current status of PGB-
0 is in preclinical studies and is expected going 
to clinical studies soon [36].  
A number of clinical studies of new boron 
delivery agents for different varieties of tumor 
were reported in Europe, Asia and in the US in 
first decade of the 2000s [3]. Until now, there is 
no new boron delivery agents have progressed 
to clinical trials besides BPA and BSH [17]. 
They are stuck in in vitro and in vivo studies 
using animals. The reason is the lack of 
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promising in vitro and in vivo tests does not 
encourage the success of expensive clinical 
biodistribution studies in humans and even 
indicates that such studies could be harmful for 
the participating. There are many steps that are 
feasible in pre-clinical study but very difficult to 
implement in clinical studies [18].  
Usually, evaluation reports of boron 
delivery agents are related to cytotoxicity, boron 
delivery agent uptake in vitro by model cell 
lines, time course biodistribution and analysis of 
boron in the tumor and in the blood for systemic 
toxicity. Biological study for every boron 
delivery agent is different depending on its 
synthesis and chemical characteristics. More 
data from biological studies is important for 
further development of boron delivery agents 
[19]. In BNCT, there is no specific standard 
protocol either in vitro/in vivo tests and clinical 
studies for dose treatment planning calculation 
and irradiation method.  Every different 
research center has its own method [16]. The 
variety of evaluation data for boron delivery 
agents from different research centers causes 
difficulty when comparing evaluation data from 
center to center and also makes it difficult to go 
to the next evaluation step with a greater 
population of patients in clinical studies [19,16]. 
Clinical studies development of new boron 
delivery agents is slow also because of the 
absence of a readily available proper neutron 
source and the high cost [21].  
Strategies to improve the number of new 
boron delivery agents through in vitro and in 
vivo tests rather clinical studies include the 
following: 1) establish centralized facility of 
biological evaluation for boron delivery agents 
including in vitro/in vivo tests and clinical 
studies which have proper laboratory facilities 
and instruments as well as a thermal and 
epithermal neutron source for irradiation 
experiment. The facility should also be staffed 
with personnel who are professionals in the 
biological aspect of BNCT. The centralization 
of biological work would provide better 
biological standards and more well-maintained 
cell and neutron sources to accumulate a more 
comprehensive database. 2) Encourage 
collaborative efforts between research centers to 
compare and determine standard dose 
prescriptions for further studies on greater 
populations or for randomized clinical trials. 3) 
Standard evaluation protocols for boron 
delivery agents must be adaptable to evaluate a 
variety of new boron delivery agents and new 
clinical objectives [19, 16, 9, 11].   
 
4. CONCLUSION AND REMARKS 
 BNCT is a potential treatment for healing 
cancer. In BNCT, a boron delivery agent is an 
important component to deliver boron to the 
tumor target. A number of boron delivery agents 
have been developed. But, to date, just two 
boron delivery agents are used in clinical 
studies, BSH and BPA. Therefore, some effort 
is required to improve the number of new boron 
delivery agents that could go through in vitro/in 
vivo test to clinical studies. So, BNCT could be 
used widely for cancer therapy.  
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